Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
PWH. People living with HIV. They’re growing older. And they’re experiencing the same illnesses of aging — CVD, kidney and liver diseases, cancers — as their HIV-seronegative counterparts.
The question is: how should they be treated?
Should the comorbidities of aging PWH be managed with the same agents and dosing regimens as people the same age who have not been fighting a chronic infective condition? How do the treatments that have increased PWH wellness and expected lifespans affect the safety and efficacy of the preferred comorbidity management options? What does the evidence-based data say?
Join Dr. Maile Young Karris, Co-Director of the San Diego Center for AIDS Research Clinical Investigations Core, and an Associate Professor from the Department of Medicine at the University of California in San Diego, as we discuss strategies to mitigate the effects of comorbidities in older people living with HIV — in this issue of eHIV Review.
Hosted on Acast. See acast.com/privacy for more information.
PrEP. For most patients, that’s a simple drug regimen that can be prescribed after a negative HIV screen. Safe. Effective. Proactive protection to stop the spread of HIV infection in MSM, cisgender, and transgender individuals.
Post-test for CME credits: https://elit.dkbmed.com/issues/228/test
Hosted on Acast. See acast.com/privacy for more information.
How will the current research advancements in long-acting ART affect clinicians’ ability to provide better care for their patients with HIV? The recent data show that the low uptake and adherence to PrEP may be largely due to the pill burden and potential stigma of daily dosing. How might the newer longer-acting PrEP regimens challenge this reluctance?
Post-test for CME credits: https://elit.dkbmed.com/issues/226/test
Hosted on Acast. See acast.com/privacy for more information.
The primary health concern for all individuals living with HIV should be managing their disease, particularly maintaining adherence to their ART treatment. Yet for many, the more immediate demands of their substance use disorder — whether for stimulants and/or opioids — take precedence and can readily become the central focus of their lives. What signals can help a clinician recognize a substance use disorder? How can they differentiate a clinical SUD from intermittent (even though harmful) substance use? What evidence-based treatments should they consider?
Post-test for CME credits: https://elit.dkbmed.com/issues/217/test
Hosted on Acast. See acast.com/privacy for more information.
People living with HIV who’ve had criminal legal involvement face significant challenges that complicate their ability to remain in the HIV care continuum. Many, while incarcerated, have stopped treatment, and once back in the community have been reluctant to resume ART. Why? What are the key drivers behind their disengagement from care? What can clinicians do to encourage these patients to return to treatment? What strategies have been tried, and what’s been shown to work? What does the evidence say?
Post-test for CME credits: https://elit.dkbmed.com/issues/213/test
Hosted on Acast. See acast.com/privacy for more information.
Widespread use of highly effective ART has increased the life expectancy of people living with HIV (PLWH) to close to that of the general population. But despite highly effective viral suppression, the risks for cardiovascular diseases continue to increase in these individuals. So too do the risks of neurocognitive impairment.
Post-test for CME credits: https://elit.dkbmed.com/issues/206/test
Hosted on Acast. See acast.com/privacy for more information.
Current ART regimens can successfully manage HIV infection in nearly all PLWH. But what happens when a patient with HIV is coinfected with a dangerous pathogen ART alone cannot handle? Two of the most common are hepatitis B and latent tuberculosis infection.
Post-test for CME credits: https://elit.dkbmed.com/issues/203/test
Hosted on Acast. See acast.com/privacy for more information.
Pregnancy and menopause — for many women, these are two of the most significant healthcare events in their lives. For WLWH (women living with HIV) and their healthcare providers, managing these life-changing periods is often complicated by many questions.
Post-test for CME credits: https://elit.dkbmed.com/issues/201
Hosted on Acast. See acast.com/privacy for more information.
In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marginalized individuals at risk for or living with HIV. In this Part 2 issue, he again calls upon two front-line clinicians in the fight to end the HIV epidemic in the U.S. — Nicky Mehtani, MD, from UCSF Medical Center in San Francisco, and Vanessa Loukas, NP, from Boston University’s Chobanian & Avedisian School of Medicine —to share their clinical approaches.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/191/test
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?
Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/183/test
Companion newsletter: https://elit.dkbmed.com/issues/182
Hosted on Acast. See acast.com/privacy for more information.
A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?
Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.
Post test for CME/CE credit: https://elit.dkbmed.com/issues/179/test
Companion newsletter: https://elit.dkbmed.com/issues/175
Hosted on Acast. See acast.com/privacy for more information.
Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? Why are so many so reluctant to accept PrEP? What can clinicians do to bridge this critical gap in essential HIV services?
These are some of the questions Guest Author Dr. Kathleen McManus, from the Division of Infectious Diseases and International Health at the University of Virginia, discusses in this issue of eHIV Review.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine appears to provide a favorable impact on weight and lipid outcomes, but with a lower genetic barrier to resistance. Which patients is it right for and in which ones should it be avoided?
Join us as we discuss Newer NNRTI Agents in Clinical Practice with Dr. Darcy Wooten from the Division of Infectious Disease at the University of California, San Diego, in this issue of eHIV Review.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
Hosted on Acast. See acast.com/privacy for more information.
Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers need to change to minimize stigma in their practices?
These are some of the questions advanced practice nurse Dallas Ducar, CEO of Transhealth, discusses in this issue of eHIV Review.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation?
Which drug combinations are right? Where does the balance between side effects and adherence lie?
These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a “return to health”; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnormalities. What causes this weight gain? How can patients most at risk for weight-related comorbidities be identified?
Join us as we discuss these and other issues with Dr. Todd Brown, Professor of Medicine and Epidemiology at Johns Hopkins University, in this eHIV Review podcast.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)?
Join Clinical Research Nurse Diane Kanjilal, manager of the Infectious Disease Clinical Research Unit at Massachusetts General Hospital, as we discuss these questions in this eHIV Review podcast.
Take our post-test to claim CME credits.
To read a companion newsletter click here.
Hosted on Acast. See acast.com/privacy for more information.
